Active 0 6 0 6 O
central 7 14 7 14 B-chronic_disease
nervous 15 22 15 22 I-chronic_disease
system 23 29 23 29 I-chronic_disease
disease 30 37 30 37 I-chronic_disease

Age 0 3 38 41 B-age
≥ 4 5 42 43 O
13 6 8 44 46 B-lower_bound
years 9 14 47 52 I-lower_bound

Clinically 0 10 53 63 O
significant 11 22 64 75 O
unrelated 23 32 76 85 O
illness 33 40 86 93 O
which 41 46 94 99 O
would 47 52 100 105 O
, 52 53 105 106 O
in 54 56 107 109 O
the 57 60 110 113 O
judgment 61 69 114 122 O
of 70 72 123 125 O
the 73 76 126 129 O
treating 77 85 130 138 O
physician 86 95 139 148 O
, 95 96 148 149 O
compromise 97 107 150 160 O
the 108 111 161 164 O
patient 112 119 165 172 O
's 119 121 172 174 O
ability 122 129 175 182 O
to 130 132 183 185 O
tolerate 133 141 186 194 O
the 142 145 195 198 O
investigational 146 161 199 214 B-treatment
agent 162 167 215 220 I-treatment
or 168 170 221 223 O
be 171 173 224 226 O
likely 174 180 227 233 O
to 181 183 234 236 O
interfere 184 193 237 246 O
with 194 198 247 251 O
the 199 202 252 255 O
study 203 208 256 261 O
procedures 209 219 262 272 O
or 220 222 273 275 O
results 223 230 276 283 O

Concomitant 0 11 284 295 O
use 12 15 296 299 O
of 16 18 300 302 O
any 19 22 303 306 O
other 23 28 307 312 O
investigational 29 44 313 328 B-treatment
or 45 47 329 331 O
anticancer 48 58 332 342 B-treatment
agent(s 59 66 343 350 I-treatment
) 66 67 350 351 I-treatment

ECOG 0 4 352 356 B-clinical_variable
performance 5 16 357 368 I-clinical_variable
status 17 23 369 375 I-clinical_variable
0 24 25 376 377 B-lower_bound
- 25 26 377 378 O
2 26 27 378 379 B-upper_bound

Evidence 0 8 380 388 O
of 9 11 389 391 O
Ewing 12 17 392 397 B-cancer
sarcoma 18 25 398 405 I-cancer
translocation 26 39 406 419 O
by 40 42 420 422 O
FISH 43 47 423 427 B-treatment
or 48 50 428 430 O
RT 51 53 431 433 B-treatment
- 53 54 433 434 I-treatment
PCR 54 57 434 437 I-treatment

Females 0 7 438 445 B-gender
of 8 10 446 448 O
childbearing 11 23 449 461 O
potential 24 33 462 471 O
as 34 36 472 474 O
well 37 41 475 479 O
as 42 44 480 482 O
males 45 50 483 488 O
and 51 54 489 492 O
their 55 60 493 498 O
partners 61 69 499 507 O
must 70 74 508 512 O
agree 75 80 513 518 B-contraception_consent
to 81 83 519 521 I-contraception_consent
use 84 87 522 525 I-contraception_consent
an 88 90 526 528 I-contraception_consent
effective 91 100 529 538 I-contraception_consent
form 101 105 539 543 I-contraception_consent
of 106 108 544 546 I-contraception_consent
contraception 109 122 547 560 I-contraception_consent
during 123 129 561 567 O
the 130 133 568 571 O
study 134 139 572 577 O
and 140 143 578 581 O
for 144 147 582 585 O
6 148 149 586 587 O
months 150 156 588 594 O
following 157 166 595 604 O
the 167 170 605 608 O
last 171 175 609 613 O
dose 176 180 614 618 O
of 181 183 619 621 O
study 184 189 622 627 O
medication 190 200 628 638 B-treatment

Histologically 0 14 639 653 O
confirmed 15 24 654 663 O
Ewing 25 30 664 669 B-cancer
sarcoma 31 38 670 677 I-cancer

Known 0 5 678 683 O
history 6 13 684 691 O
of 14 16 692 694 O
MDS 17 20 695 698 B-cancer
or 21 23 699 701 O
AML 24 27 702 705 B-cancer

Known 0 5 706 711 O
hypersensitivity 6 22 712 728 O
reaction 23 31 729 737 O
to 32 34 738 740 O
temozolomide 35 47 741 753 B-allergy_name
or 48 50 754 756 O
any 51 54 757 760 O
of 55 57 761 763 O
its 58 61 764 767 O
components 62 72 768 778 O
, 72 73 778 779 O
or 74 76 780 782 O
dacarbazine 77 88 783 794 B-allergy_name
( 89 90 795 796 I-allergy_name
DTIC 90 94 796 800 I-allergy_name
) 94 95 800 801 I-allergy_name
if 96 98 802 804 O
enrolled 99 107 805 813 O
on 108 110 814 816 O
ARM 111 114 817 820 O
1 115 116 821 822 O
or 117 119 823 825 O
irinotecan 120 130 826 836 B-allergy_name
or 131 133 837 839 O
any 134 137 840 843 O
of 138 140 844 846 O
its 141 144 847 850 O
components 145 155 851 861 O
if 156 158 862 864 O
enrolled 159 167 865 873 O
on 168 170 874 876 O
ARM 171 174 877 880 O
2 175 176 881 882 O

Known 0 5 883 888 O
hypersensitivity 6 22 889 905 O
to 23 25 906 908 O
any 26 29 909 912 O
of 30 32 913 915 O
the 33 36 916 919 O
components 37 47 920 930 B-allergy_name
of 48 50 931 933 I-allergy_name
niraparib 51 60 934 943 I-allergy_name
or 61 63 944 946 O
prior 64 69 947 952 O
hypersensitivity 70 86 953 969 O
reactions 87 96 970 979 O
to 97 99 980 982 O
that 100 104 983 987 O
class 105 110 988 993 B-allergy_name
of 111 113 994 996 I-allergy_name
drugs 114 119 997 1002 I-allergy_name

Known 0 5 1003 1008 O
persistent 6 16 1009 1019 B-clinical_variable
( 17 18 1020 1021 O
> 18 19 1021 1022 O
4 20 21 1023 1024 B-lower_bound
weeks 22 27 1025 1030 I-lower_bound
) 27 28 1030 1031 O

Life 0 4 1032 1036 B-clinical_variable
expectancy 5 15 1037 1047 I-clinical_variable
of 16 18 1048 1050 O
≥ 19 20 1051 1052 O
3 21 22 1053 1054 B-lower_bound
months 23 29 1055 1061 I-lower_bound

Measurable 0 10 1062 1072 O
disease 11 18 1073 1080 O
on 19 21 1081 1083 O
CT 22 24 1084 1086 B-treatment
or 25 27 1087 1089 O
MRI 28 31 1090 1093 B-treatment
by 32 34 1094 1096 O
RECIST 35 41 1097 1103 O
1.1 42 45 1104 1107 O

Must 0 4 1108 1112 O
be 5 7 1113 1115 O
willing 8 15 1116 1123 O
to 16 18 1124 1126 O
undergo 19 26 1127 1134 O
tumor 27 32 1135 1140 B-treatment
biopsy 33 39 1141 1147 I-treatment
at 40 42 1148 1150 O
study 43 48 1151 1156 O
entry 49 54 1157 1162 O
for 55 58 1163 1166 O
biologic 59 67 1167 1175 B-treatment
correlates 68 78 1176 1186 I-treatment

Other 0 5 1187 1192 O
clinically 6 16 1193 1203 O
significant 17 28 1204 1215 O
malignant 29 38 1216 1225 B-cancer
disease 39 46 1226 1233 I-cancer
diagnosed 47 56 1234 1243 O
within 57 63 1244 1250 O
the 64 67 1251 1254 O
previous 68 76 1255 1263 B-upper_bound
5 77 78 1264 1265 I-upper_bound
years 79 84 1266 1271 I-upper_bound
, 84 85 1271 1272 O
excluding 86 95 1273 1282 O
intra 96 101 1283 1288 B-cancer
- 101 102 1288 1289 I-cancer
epithelial 102 112 1289 1299 I-cancer
cervical 113 121 1300 1308 I-cancer
neoplasia 122 131 1309 1318 I-cancer
or 132 134 1319 1321 O
non 135 138 1322 1325 B-cancer
- 138 139 1325 1326 I-cancer
melanoma 139 147 1326 1334 I-cancer
skin 148 152 1335 1339 I-cancer
cancer 153 159 1340 1346 I-cancer

Patients 0 8 1347 1355 O
must 9 13 1356 1360 O
have 14 18 1361 1365 O
received 19 27 1366 1374 O
as 28 30 1375 1377 O
a 31 32 1378 1379 O
minimum 33 40 1380 1387 O
a 41 42 1388 1389 O
first 43 48 1390 1395 B-treatment
line 49 53 1396 1400 I-treatment
chemotherapy 54 66 1401 1413 I-treatment
regimen 67 74 1414 1421 I-treatment
consisting 75 85 1422 1432 O
of 86 88 1433 1435 O
at 89 91 1436 1438 O
least 92 97 1439 1444 O
2 98 99 1445 1446 B-lower_bound
of 100 102 1447 1449 O
the 103 106 1450 1453 O
following 107 116 1454 1463 O
agents 117 123 1464 1470 O
: 123 124 1470 1471 O
doxorubicin 125 136 1472 1483 B-treatment
, 136 137 1483 1484 O
cyclophosphamide 138 154 1485 1501 B-treatment
, 154 155 1501 1502 O
ifosfamide 156 166 1503 1513 B-treatment
, 166 167 1513 1514 O
etoposide 168 177 1515 1524 B-treatment

Patients 0 8 1525 1533 O
or 9 11 1534 1536 O
their 12 17 1537 1542 O
legal 18 23 1543 1548 O
representative 24 38 1549 1563 O
( 39 40 1564 1565 O
if 40 42 1565 1567 O
the 43 46 1568 1571 O
patient 47 54 1572 1579 O
is 55 57 1580 1582 O
< 58 59 1583 1584 O
18 60 62 1585 1587 B-upper_bound
years 63 68 1588 1593 I-upper_bound
old 69 72 1594 1597 O
) 72 73 1597 1598 O
must 74 78 1599 1603 O
be 79 81 1604 1606 O
able 82 86 1607 1611 O
to 87 89 1612 1614 O
read 90 94 1615 1619 O
, 94 95 1619 1620 O
understand 96 106 1621 1631 O
and 107 110 1632 1635 O
provide 111 118 1636 1643 O
written 119 126 1644 1651 O
informed 127 135 1652 1660 O
consent 136 143 1661 1668 O
to 144 146 1669 1671 O
participate 147 158 1672 1683 O
in 159 161 1684 1686 O
the 162 165 1687 1690 O
trial 166 171 1691 1696 O

Patients 0 8 1697 1705 O
who 9 12 1706 1709 O
have 13 17 1710 1714 O
received 18 26 1715 1723 O
allogeneic 27 37 1724 1734 O
hematopoietic 38 51 1735 1748 B-treatment
stem 52 56 1749 1753 I-treatment
cell 57 61 1754 1758 I-treatment
transplantation 62 77 1759 1774 I-treatment
will 78 82 1775 1779 O
be 83 85 1780 1782 O
eligible 86 94 1783 1791 O
6 95 96 1792 1793 B-upper_bound
months 97 103 1794 1800 I-upper_bound
after 104 109 1801 1806 I-upper_bound
the 110 113 1807 1810 O
procedure 114 123 1811 1820 O
provided 124 132 1821 1829 O
there 133 138 1830 1835 O
is 139 141 1836 1838 O
no 142 144 1839 1841 O
evidence 145 153 1842 1850 O
of 154 156 1851 1853 O
active 157 163 1854 1860 O
graft 164 169 1861 1866 B-chronic_disease
- 169 170 1866 1867 I-chronic_disease
versus 170 176 1867 1873 I-chronic_disease
- 176 177 1873 1874 I-chronic_disease
host 177 181 1874 1878 I-chronic_disease
disease 182 189 1879 1886 I-chronic_disease
and 190 193 1887 1890 O
immunosuppressive 194 211 1891 1908 B-treatment
treatment 212 221 1909 1918 I-treatment
has 222 225 1919 1922 O
been 226 230 1923 1927 O
discontinued 231 243 1928 1940 O
for 244 247 1941 1944 O
at 248 250 1945 1947 O
least 251 256 1948 1953 O
30 257 259 1954 1956 B-lower_bound
days 260 264 1957 1961 I-lower_bound

Patients 0 8 1962 1970 O
who 9 12 1971 1974 O
have 13 17 1975 1979 O
undergone 18 27 1980 1989 O
autologous 28 38 1990 2000 B-treatment
hematopoietic 39 52 2001 2014 I-treatment
stem 53 57 2015 2019 I-treatment
cell 58 62 2020 2024 I-treatment
transplantation 63 78 2025 2040 I-treatment
are 79 82 2041 2044 O
eligible 83 91 2045 2053 O
once 92 96 2054 2058 O
they 97 101 2059 2063 O
have 102 106 2064 2068 O
recovered 107 116 2069 2078 O
from 117 121 2079 2083 O
all 122 125 2084 2087 O
toxicities 126 136 2088 2098 O
from 137 141 2099 2103 O
therapy 142 149 2104 2111 B-treatment

Patients 0 8 2112 2120 O
with 9 13 2121 2125 O
baseline 14 22 2126 2134 O
QTc 23 26 2135 2138 B-clinical_variable
> 27 28 2139 2140 O
480 29 32 2141 2144 B-lower_bound
msec 33 37 2145 2149 I-lower_bound

Patients 0 8 2150 2158 O
with 9 13 2159 2163 O
central 14 21 2164 2171 B-chronic_disease
nervous 22 29 2172 2179 I-chronic_disease
system 30 36 2180 2186 I-chronic_disease
disease 37 44 2187 2194 I-chronic_disease
are 45 48 2195 2198 O
eligible 49 57 2199 2207 O
for 58 61 2208 2211 O
enrollment 62 72 2212 2222 O
if 73 75 2223 2225 O
they 76 80 2226 2230 O
have 81 85 2231 2235 O
received 86 94 2236 2244 O
prior 95 100 2245 2250 B-treatment
radiotherapy 101 113 2251 2263 I-treatment
or 114 116 2264 2266 O
surgery 117 124 2267 2274 B-treatment
to 125 127 2275 2277 O
sites 128 133 2278 2283 O
of 134 136 2284 2286 O
central 137 144 2287 2294 B-cancer
nervous 145 152 2295 2302 I-cancer
system 153 159 2303 2309 I-cancer
metastatic 160 170 2310 2320 I-cancer
disease 171 178 2321 2328 I-cancer
, 178 179 2328 2329 O
have 180 184 2330 2334 O
been 185 189 2335 2339 O
off 190 193 2340 2343 O
glucocorticoids 194 209 2344 2359 B-treatment
for 210 213 2360 2363 O
at 214 216 2364 2366 O
least 217 222 2367 2372 O
4 223 224 2373 2374 B-lower_bound
weeks 225 230 2375 2380 I-lower_bound
, 230 231 2380 2381 O
have 232 236 2382 2386 O
no 237 239 2387 2389 O
overt 240 245 2390 2395 O
evidence 246 254 2396 2404 O
of 255 257 2405 2407 O
neurological 258 270 2408 2420 O
deficit 271 278 2421 2428 O
and 279 282 2429 2432 O
are 283 286 2433 2436 O
≥ 287 288 2437 2438 O
6 289 290 2439 2440 B-lower_bound
weeks 291 296 2441 2446 I-lower_bound
from 297 301 2447 2451 O
completion 302 312 2452 2462 O
of 313 315 2463 2465 O
brain 316 321 2466 2471 B-treatment
irradiation 322 333 2472 2483 I-treatment

Pregnant 0 8 2484 2492 B-pregnancy
patients 9 17 2493 2501 O
or 18 20 2502 2504 O
patients 21 29 2505 2513 O
who 30 33 2514 2517 O
are 34 37 2518 2521 O
breast 38 44 2522 2528 O
feeding 45 52 2529 2536 O

Recurrent 0 9 2537 2546 O
or 10 12 2547 2549 O
refractory 13 23 2550 2560 O
tumors 24 30 2561 2567 B-cancer
with 31 35 2568 2572 O
no 36 38 2573 2575 O
known 39 44 2576 2581 O
curative 45 53 2582 2590 B-treatment
treatment 54 63 2591 2600 I-treatment
options 64 71 2601 2608 O
according 72 81 2609 2618 O
to 82 84 2619 2621 O
the 85 88 2622 2625 O
judgment 89 97 2626 2634 O
of 98 100 2635 2637 O
the 101 104 2638 2641 O
investigator 105 117 2642 2654 O

Subjects 0 8 2655 2663 O
capable 9 16 2664 2671 O
of 17 19 2672 2674 O
pregnancy 20 29 2675 2684 B-pregnancy
( 30 31 2685 2686 O
post 31 35 2686 2690 O
menarche 36 44 2691 2699 O
and 45 48 2700 2703 O
not 49 52 2704 2707 O
post 53 57 2708 2712 O
- 57 58 2712 2713 O
menopausal 58 68 2713 2723 O
, 68 69 2723 2724 O
defined 70 77 2725 2732 O
as 78 80 2733 2735 O
over 81 85 2736 2740 O
12 86 88 2741 2743 B-lower_bound
months 89 95 2744 2750 I-lower_bound
since 96 101 2751 2756 O
final 102 107 2757 2762 O
menstrual 108 117 2763 2772 O
period 118 124 2773 2779 O
) 124 125 2779 2780 O
must 126 130 2781 2785 O
have 131 135 2786 2790 O
a 136 137 2791 2792 O
negative 138 146 2793 2801 B-pregnancy
pregnancy 147 156 2802 2811 I-pregnancy
test 157 161 2812 2816 O
within 162 168 2817 2823 O
7 169 170 2824 2825 B-upper_bound
days 171 175 2826 2830 I-upper_bound
prior 176 181 2831 2836 I-upper_bound
to 182 184 2837 2839 O
first 185 190 2840 2845 O
dose 191 195 2846 2850 O

Time 0 4 2851 2855 O
elapsed 5 12 2856 2863 O
from 13 17 2864 2868 O
previous 18 26 2869 2877 O
therapy 27 34 2878 2885 B-treatment
must 35 39 2886 2890 O
be 40 42 2891 2893 O
≥ 43 44 2894 2895 O
3 45 46 2896 2897 B-lower_bound
weeks 47 52 2898 2903 I-lower_bound
for 53 56 2904 2907 O
systemic 57 65 2908 2916 B-treatment
therapy 66 73 2917 2924 I-treatment
, 73 74 2924 2925 O
≥ 75 76 2926 2927 O
2 77 78 2928 2929 B-lower_bound
weeks 79 84 2930 2935 I-lower_bound
for 85 88 2936 2939 O
radiation 89 98 2940 2949 B-treatment
therapy 99 106 2950 2957 I-treatment
or 107 109 2958 2960 O
major 110 115 2961 2966 B-treatment
surgery 116 123 2967 2974 I-treatment

≥ 0 1 2975 2976 O
Grade 2 7 2977 2982 B-lower_bound
2 8 9 2983 2984 I-lower_bound
neutropenia 10 21 2985 2996 B-clinical_variable
, 21 22 2996 2997 O
≥ 23 24 2998 2999 O
Grade 25 30 3000 3005 O
2 31 32 3006 3007 O
thrombocytopenia 33 49 3008 3024 B-clinical_variable
or 50 52 3025 3027 O
> 53 54 3028 3029 O
Grade 55 60 3030 3035 B-lower_bound
3 61 62 3036 3037 I-lower_bound
anemia 63 69 3038 3044 B-chronic_disease
from 70 74 3045 3049 O
prior 75 80 3050 3055 B-treatment
cancer 81 87 3056 3062 I-treatment
therapy 88 95 3063 3070 I-treatment

